Evidence map›Paper›PMID 36920943›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2023

Development of the Safe and Broad-Spectrum Aldehyde and Ketoamide Mpro inhibitors Derived from the Constrained α, γ-AA Peptide Scaffold.

Lei Wang, Chunlong Ma, Michael Dominic Sacco, Songyi Xue, Mentalla Mahmoud, Laurent Calcul, Yu Chen, Jun Wang, Jianfeng Cai

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Lei WangDepartment of Chemistry, University of South Florida, 4202 E. Fowler Ave., Tampa, FL 33620, USA.
Chunlong MaDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona, 85721, USA.
Michael Dominic SaccoDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, 4202 E. Fowler Ave., Tampa, FL 33620, USA.
Songyi XueDepartment of Chemistry, University of South Florida, 4202 E. Fowler Ave., Tampa, FL 33620, USA.
Mentalla MahmoudDepartment of Chemistry, University of South Florida, 4202 E. Fowler Ave., Tampa, FL 33620, USA.
Laurent CalculDepartment of Chemistry, University of South Florida, 4202 E. Fowler Ave., Tampa, FL 33620, USA.
Yu ChenDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, 4202 E. Fowler Ave., Tampa, FL 33620, USA.ORCID http://orcid.org/0000-0002-5115-3600
Jun WangDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona, 85721, USA.ORCID http://orcid.org/0000-0002-4845-4621
Jianfeng CaiDepartment of Chemistry, University of South Florida, 4202 E. Fowler Ave., Tampa, FL 33620, USA.ORCID http://orcid.org/0000-0003-3106-3306
University of South Florida · USRutgers, The State University of New Jersey · USUniversity of Arizona · US

Funding

Development of dual inhibitors targeting the viral main protease and the host cathepsin L as SARS-CoV-2 antiviralsR01AI158775 · NIAID · UNIVERSITY OF ARIZONA · PI Jun Wang · 2021 to 2026
$3.6M
Novel polymer biomaterials combating C. difficile infectionR01AI149852 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI CAI, JIANFENG, SUN, XINGMIN · 2019 to 2023
$1.9M
Antimicrobial agents derived from AApeptide biomaterialsR01AI152416 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI CAI, JIANFENG · 2020 to 2024
$1.9M
NIAID NIH HHS R01 AI149852NIAID NIH HHS R01 AI152416NIAID NIH HHS R01 AI158775NIH HHS R01AI152416, R01AI149852
6 · The paper itself

Abstract

SARS-CoV-2 is still wreaking havoc all over the world with surging morbidity and high mortality. The main protease (M

Indexed as

Coronavirus OC43, HumanCOVID-19Antiviral AgentsHumansPeptidesProtease InhibitorsSARS-CoV-2Antiviral AgentsPeptidesProtease Inhibitorsbroad-spectrum activityCOVID-19Mpro inhibitorSARS-CoV-2X-ray structure

Identifiers

PMID36920943
PMCPMC10330001
OpenAlexW4324311156

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.